₩ 50100
Key Takeaways
Risk factor
Meaningful price volatility
Profitability factor
Greatly overvalued vs peers
About
SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is overvalued on EV/EBITDA.
Target Price
The average target price of 302440.KS is 36245 and suggests 31% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation
